BL-M08D1 clinical trials
How each study uses BL-M08D1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BL-M08D1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- BL-M08D1
- 8
Studies by the year they started
8 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test BL-M08D1.
- Dec 2026A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid TumorsPhase 1 · Sichuan Baili Pharmaceutical Co., Ltd.
- Jun 2027A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid MalignanciesPhase 1 · Sichuan Baili Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses BL-M08D1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid TumorsRecruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT07841925Written as BL-M08D1
- A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid TumorsRecruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT07780318Written as BL-M08D1
- A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaNot yet recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT07818499Written as BL-M08D1
- A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid TumorsNot yet recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT07818486Written as BL-M08D1
- A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid TumorsNot yet recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT07793825Written as BL-M08D1
- A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsNot yet recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07788950Written as BL-M08D1
- A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT06718621Written as BL-M08D1
- A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid MalignanciesRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT06718634Written as BL-M08D1